Search

Barbara Brandhuber Phones & Addresses

  • Boulder, CO
  • Como, CO
  • Colorado Springs, CO
  • Fort Collins, CO
  • Golden, CO
  • Golden, CO
  • Dayton, OH
  • Juneau, AK

Work

Company: Loxo oncology at lilly Jan 2019 Position: Vice president, small molecule biology

Education

Degree: Doctorates, Doctor of Philosophy School / High School: University of Colorado Boulder Specialities: Philosophy, Chemistry

Industries

Pharmaceuticals

Resumes

Resumes

Barbara Brandhuber Photo 1

Vice President, Small Molecule Biology

View page
Location:
Boulder, CO
Industry:
Pharmaceuticals
Work:
Loxo Oncology at Lilly
Vice President, Small Molecule Biology

Loxo Oncology, Inc.
Vice President, Small Molecule Biology

Loxo Oncology, Inc.
Executive Director, Discovery Biology

Array Biopharma Inc. Oct 1998 - Jul 2017
Executive Director, Structural Biology, Early Discovery

Amgen 1994 - 1998
Research Scientist Ii, Protein Chemistry and Crystallography
Education:
University of Colorado Boulder
Doctorates, Doctor of Philosophy, Philosophy, Chemistry
Boston University
Masters, Management
University of Dayton
Bachelors, Chemistry

Publications

Us Patents

Method Of Structure-Based Drug Design To Create Or Improve Modular Of Il-1 Activity Which Mind To The Interleukin-1 Type 1 Receptor

View page
US Patent:
20040014643, Jan 22, 2004
Filed:
Mar 14, 2003
Appl. No.:
10/389012
Inventors:
Barbara Brandhuber - Golden CO, US
Guy Vigers - Boulder CO, US
Assignee:
Array BioPharma Inc.
International Classification:
A61K038/16
G06F019/00
G01N033/48
G01N033/50
C07K014/715
US Classification:
514/007000, 514/012000, 530/350000, 702/019000
Abstract:
Crystals comprising a modified interleukin-1 type 1 receptor (IL-1R1) and one or more modulators of IL-1 activity are described. Methods of identifying potential inhibitors of IL-1 activity are also described. Compositions and methods for the treatment of IL-1 mediated diseases, such as rheumatoid arthritis, osteoarthritis, and other inflammatory conditions, are described.

Substituted Pyrazolo[1,5-A]Pyridine Compounds As Ret Kinase Inhibitors

View page
US Patent:
20220313676, Oct 6, 2022
Filed:
Dec 1, 2020
Appl. No.:
17/108528
Inventors:
- Boulder CO, US
Sean ARONOW - Boulder CO, US
James F. BLAKE - Boulder CO, US
Barbara J. BRANDHUBER - Boulder CO, US
James COLLIER - Boulder CO, US
Adam COOK - Boulder CO, US
Julia HAAS - Boulder CO, US
Yutong JIANG - Boulder CO, US
Gabrielle R. KOLAKOWSKI - Boulder CO, US
Elizabeth A. MCFADDIN - Boulder CO, US
Megan L. MCKENNEY - Boulder CO, US
Oren T. MCNULTY - Boulder SO, US
Andrew T. METCALF - Boulder CO, US
David A. MORENO - Boulder CO, US
Ginelle A. RAMANN - Boulder CO, US
Tony P. TANG - Boulder CO, US
Li REN - Boulder CO, US
Shane M. WALLS - Boulder CO, US
International Classification:
A61K 31/4545
A61K 31/4162
C07D 471/04
A61P 1/00
A61P 35/00
A61P 35/02
A61K 31/444
A61K 31/497
A61K 31/501
A61K 31/506
A61K 31/5377
A61K 45/06
A61P 1/12
Abstract:
Provided herein are compounds of the Formula I:or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X, X, X, X, Ring D, E, R, R, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

7,8-Dihydro-4H-Pyrazolo[4,3-C]Azepine-6-One Compounds

View page
US Patent:
20220251096, Aug 11, 2022
Filed:
Aug 3, 2020
Appl. No.:
17/628659
Inventors:
- Indianapolis IN, US
Barbara Jean BRANDHUBER - Golden CO, US
International Classification:
C07D 487/04
A61P 35/00
Abstract:
Disclosed herein are compounds of Formula I: wherein Ris CH3 or CH2CH3; and pharmaceutically acceptable salts thereof, which are useful for treating cancer.

Substituted Pyrazolo[1,5-A]Pyridine Compounds As Ret Kinase Inhibitors

View page
US Patent:
20230090520, Mar 23, 2023
Filed:
Nov 19, 2021
Appl. No.:
17/530702
Inventors:
- Boulder CO, US
Sean ARONOW - Boulder CO, US
James F. BLAKE - Boulder CO, US
Barbara J. BRANDHUBER - Boulder CO, US
Adam COOK - Boulder CO, US
Julia HAAS - Boulder CO, US
Yutong JIANG - Boulder CO, US
Gabrielle R. KOLAKOWSKI - Boulder CO, US
Elizabeth A. MCFADDIN - Boulder CO, US
Megan L. MCKENNEY - Boulder CO, US
Oren T. MCNULTY - Boulder CO, US
Andrew T. METCALF - Boulder CO, US
David A. MORENO - Boulder CO, US
Tony P. TANG - Boulder CO, US
Li REN - Boulder CO, US
International Classification:
A61K 31/496
C07D 471/04
A61P 1/12
A61P 35/04
C07D 519/00
A61P 35/02
A61P 35/00
A61K 31/444
A61K 31/4985
A61K 31/4995
A61K 31/506
A61K 31/5377
A61K 45/06
A61K 31/551
Abstract:
Provided herein are compounds of the Formula I:and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X, X, X, X, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

Point Mutations In Trk Inhibitor-Resistant Cancer And Methods Relating To The Same

View page
US Patent:
20210164055, Jun 3, 2021
Filed:
Feb 1, 2021
Appl. No.:
17/163930
Inventors:
- Stamford CT, US
- Boulder CO, US
James F. Blake - Boulder CO, US
Gabrielle R. Kolakowski - Boulder CO, US
Barbara J. Brandhuber - Boulder CO, US
Steven W. Andrews - Boulder CO, US
International Classification:
C12Q 1/6886
A61K 31/5025
A61K 31/519
G01N 33/574
Abstract:
Provided herein are methods of treating a subject having a cancer, methods of selecting a treatment for a subject having a cancer, methods of selecting a subject having a cancer for a treatment that does not include a Trk inhibitor, methods of determining the likelihood that a subject having a cancer will have a positive response to a treatment with a Trk inhibitor, methods of predicting the efficacy of a Trk inhibitor in a subject having cancer, methods of determining a subject's risk for developing a Trk inhibitor-resistant cancer, and methods of determining the presence of a Trk inhibitor-resistant cancer in a subject, based on the detection of a cell from a sample from the subject that has at least one of the point mutations in NTRK1 and/or NTRK2 and/or NTRK3.

Substituted Pyrazolo[1,5-A]Pyridine Compounds As Ret Kinase Inhibitors

View page
US Patent:
20200383966, Dec 10, 2020
Filed:
Sep 23, 2019
Appl. No.:
16/579150
Inventors:
- Boulder CO, US
Sean ARONOW - Boulder CO, US
James F. BLAKE - Boulder CO, US
Barbara J. BRANDHUBER - Boulder CO, US
James COLLIER - Boulder CO, US
Adam COOK - Boulder CO, US
Julia HAAS - Boulder CO, US
Yutong JIANG - Boulder CO, US
Gabrielle R. KOLAKOWSKI - Boulder CO, US
Elizabeth A. McFADDIN - Boulder CO, US
Megan L. McKENNEY - Boulder CO, US
Oren T. McNULTY - Boulder CO, US
Andrew T. METCALF - Boulder CO, US
David A. MORENO - Boulder CO, US
Ginelle A. RAMANN - Boulder CO, US
Tony P. TANG - Boulder CO, US
Li REN - Boulder CO, US
Shane M. WALLS - Boulder CO, US
International Classification:
A61K 31/4545
A61K 31/4162
C07D 471/04
A61P 1/00
A61P 35/00
A61P 35/02
A61K 31/444
A61K 31/497
A61K 31/501
A61K 31/506
A61K 31/5377
A61K 45/06
A61P 1/12
Abstract:
Provided herein are compounds of the Formula I:or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X, X, X, X, Ring D, E, R, R, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

Bicyclic Urea, Thiourea, Guanidine And Cyanoguanidine Compounds Useful For The Treatment Of Pain

View page
US Patent:
20190270749, Sep 5, 2019
Filed:
May 17, 2019
Appl. No.:
16/415575
Inventors:
- Boulder CO, US
Steven Wade Andrews - Longmont CO, US
James F. Blake - Boulder CO, US
Barbara J. Brandhuber - Golden CO, US
Julia Haas - Boulder CO, US
Yutong Jiang - Boulder CO, US
Timothy Kercher - San Diego CA, US
Gabrielle R. Kolakowski - Longmont CO, US
Allen A. Thomas - Kearney NE, US
Shannon L. Winski - Boulder CO, US
Assignee:
Array BioPharma Inc. - Boulder CO
International Classification:
C07D 491/048
C07D 409/14
C07D 401/14
C07D 231/52
C07D 231/56
C07D 401/04
C07D 453/02
C07D 413/12
C07D 405/12
C07D 403/14
C07D 403/04
C07D 403/02
C07D 401/12
C07D 231/54
C07D 231/40
C07D 405/14
C07D 471/08
Abstract:
Compounds of Formula I:or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.

Substituted Pyrazolo[1,5-A]Pyridine Compounds As Ret Kinase Inhibitors

View page
US Patent:
20190183886, Jun 20, 2019
Filed:
Oct 29, 2018
Appl. No.:
16/173100
Inventors:
- Boulder CO, US
Sean Aronow - Boulder CO, US
James F. Blake - Boulder CO, US
Barbara J. Brandhuber - Boulder CO, US
Adam Cook - Boulder CO, US
Julia Haas - Boulder CO, US
Yutong Jiang - Boulder CO, US
Gabrielle R. Kolakowski - Boulder CO, US
Elizabeth A. McFaddin - Boulder CO, US
Megan L. McKenney - Boulder CO, US
Oren T. McNulty - Boulder CO, US
Andrew T. Metcalf - Boulder CO, US
David A. Moreno - Boulder CO, US
Tony P. Tang - Boulder CO, US
Li Ren - Boulder CO, US
International Classification:
A61K 31/496
C07D 471/04
A61K 31/551
A61K 31/4985
A61P 35/00
A61K 31/444
A61K 45/06
A61P 1/12
A61K 31/506
A61K 31/5377
A61P 35/02
C07D 519/00
A61P 35/04
A61K 31/4995
Abstract:
Provided herein are compounds of the Formula I:and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X, X, X, X, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
Barbara Jean Brandhuber from Boulder, CO, age ~65 Get Report